Development of an inactivated vaccine candidate for SARS-CoV-2

Cited by (1,435)

Items 1,401–1,435 of 1,435

1. Effect of Inactivated Vaccines Against SARS-CoV-2 on Immunogenicity Outcome
   Yuke Ma, Yukuan Du, Jingnan Yang, Huichao Wang, Xuhong Lin · 2024 · Disaster Medicine and Public Health Preparedness
2. Improving SARS-CoV-2 variants monitoring in the absence of genomic surveillance capabilities: a serological study in Bolivian blood donors in October 2021 and June 2022
   Lucia Inchauste, Elif Nurtop, Lissete Bautista Machicado, Yanine Leigue Roth, Shirley Lenz Gonzales, Maria Luisa Herrera, Katty Mina Villafan, Pedro Mamani Mamani, Marcelo Ramos Espinoza, Juan Carlos Pavel Suarez et al. · 2025 · eLife
3. Removal and inactivation of coronavirus in water and wastewater treatments plants: a critical review—global perspective
   A.K. Priya, V. Yogeshwaran, Jayaraman Sethuraman Sudarsan · 2025 · Journal of Umm Al-Qura University for Engineering and Architecture
4. Prevention of incident SARS-CoV-2 infection through combined intranasal and intradermal administration of the GLS-5310 DNA vaccine during the Omicron outbreak
   Joel N. Maslow, Javier O Morales-Ramirez, Christine C. Roberts, Susan E. Spruill, Deborah Kane, Melissa Gulley, Joel Muñoz-Coreano, Sonia Velazquez-Navarro, Jay W. Meyer, Sagar B. Kudchodkar et al. · 2025 · Research Square
5. COVID-19 Disease
   Christopher P. Conlon, John D. Firth · 2020
6. Evaluation of broad-spectrum protection by novel mRNA vaccines against SARS-CoV-2 variants (Delta, Omicron-BA.5, XBB-EG.5) in the golden hamster model
   Tong Yu, Jun-Hong Xing, Xinyu Zhuang, Mingyao Tian · 2025 · Virology Journal
7. An Overview of Destroying SARS-CoV-2 and Proof of the Relationship Between Climate Changes and Airborne Dust on SARS-CoV-2 Prevalence
   Mohamed Madani, Hasi Rani Barai, Dalal Mohamed Alshangiti, Sheikha A. Alkhursani, Samera Ali Al-Gahtany, Mohamed Mohamady Ghobashy, Gamal Abdel Nasser Atia, Zubair Ahmad, Farhat S. Khan, Paritosh Barai et al. · 2025 · Vector-Borne and Zoonotic Diseases
8. EVENTOS ADVERSOS DAS VACINAS CONTRA COVID-19 EM UM ESTADO DO NORDESTE BRASILEIRO
   André Felipe de Castro Pereira Chaves, Telma Maria Evangelista de Araújo, GABRIELLY SOARES SILVA BEZERRA, Olívia Dias de Araújo, Chrystiany Plácido de Brito Vieira, Beatriz Mourão Pereira · 2025 · Enfermagem em Foco
9. Additional file 1 of Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial
   Feng, Yongliang, Chen, Jing, Tian Yao, Chang, Yue, Li, Xiaoqing, Rongqin Xing, Li, Hong, Ruixue Xie, Zhang, Xiaohong, Wei, Zhiyun et al. · 2021 · Figshare
10. Additional file 1 of Adjuvant screening of the Senecavirus A inactivated vaccine in mice and evaluation of its immunogenicity in pigs
    Zhang, Jinyong, Peng Wang, Li, Zhuoxin · 2024 · Figshare
11. Additional file 1 of Neutralizing antibody responses assessment after vaccination in people living with HIV using a surrogate neutralization assay
    Batchi-Bouyou, Armel Landry, Jean Claude Djontu, Ingoba, Line Lobaloba et al. · 2024 · Figshare
12. Additional file 1 of Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint
    Chen, Xinhua, Wang, Wei, Chen, Xinghui, Wu, Qianhui, Sun, Ruijia, Shijia Ge, Zheng, Nan, Lu, Wanying, Yang, Juan, Lance Everett Rodewald et al. · 2022 · Figshare
13. Additional file 1 of Replication kinetics and infectivity of SARS-CoV-2 variants of concern in common cell culture models
    Lena Mautner, Mona Hoyos, Alexandra Dangel, Carola Berger, Anja Ehrhardt, Armin E. Baiker · 2022 · Figshare
14. Additional file 1 of Precision therapeutic targets for COVID-19
    Zachary A. Krumm, Grace M. Lloyd, Francis, Connor P., Lith H. Nasif, Mitchell, Duane A., Golde, Todd E., Benoit I. Giasson, Yuxing Xia · 2021 · Figshare
15. Lymphoid Organs Remodeling in Non‐Obese Diabetic Goto‐Kakizaki Rats Immunized With SARS ‐ CoV ‐2 Antigens
    Sara Araújo Pereira, Mariana Cruz Lazzarin, M.L. Dagli et al. · 2026 · The FASEB Journal
16. mRNA–Lipid Hybrid Nanovaccines: A Next-Generation Strategy for Broad-Spectrum Viral Immunity
    Rehan Haider, Zeba Ahmed, Sambreen Zameer · 2026 · i-manager s Journal on Life Sciences
17. COVID-19 challenges and its therapeutics
    Liguo Liang, Yang Li, Siming Lu, Jialong Wang, Hangping Yao · 2026 · Elsevier eBooks
18. Application of lentiviral vector in vaccinology
    Min‐Wen Ku · 2020 · theses.fr (ABES)
19. Exploration of autophagy modulation in cancer and infectious diseases
    Eloïne Bestion · 2021 · theses.fr (ABES)
20. Seroepidemiology of emerging viruses in Bolivia
    Lucia Inchauste Jordan · 2023 · theses.fr (ABES)
21. Ce doped ZnO Catalyst for Degradation of Triethylamine under Solar Light: A Comparative Study of Sol-Gel and Co-precipitation Synthesis
    Netaji P. Mali, Amol S. Bhosale, Shaila B. Dhotre · 2026 · Asian Journal of Chemistry
22. O futuro pode repetir o passado: um olhar a partir de iniciativas bem-sucedidas de gestão e desenvolvimento tecnológico em saúde nos contextos de crises sanitárias – o caso da Fiocruz e a vacina AstraZeneca
    Eduardo Francisco dos Santos Gnisci, Cláudia Souza Passador · 2026 · Revista de gestão dos países de língua portuguesa
23. Performance of Three Commercial Rapid Diagnostic Tests for Detection of IgM and IgG Antibodies Against SARS‐CoV‐2
    Moyra Machado Portilho, Stephane Fraga de Oliveira Tosta, Maysa Pellizzaro et al. · 2026 · Immunity Inflammation and Disease
24. Integrated workflow for production and in vitro characterization of equine anti-SARS-CoV-2 hyperimmune serum with epitope mapping
    Karla S. Evangelista, Emerson de Castro Barbosa, Adriana de Souza Andrade et al. · 2026 · Journal of Immunological Methods
25. Revisiting of the Role of CD8 + T‐Cells in Vaccine‐Induced Protection Against SARS‐CoV‐2 in Macaques via Mathematical Modeling
    Malik Muhammad Ibrahim, Jong Hyuk Byun, Malik Muhammad Naeem Mannan, Kwang Su Kim · 2026 · Complexity
26. Regulation of antiviral immunity by PD-1 during respiratory syncitial virus infection and upon vaccination
    Linmar Rodríguez‐Guilarte, Constanza Méndez, M. Fernanda Rojas, Patricia Pereira-Sánchez, Mariana Ríos, José T. Muñóz, Mónica A. Farías, Susan M. Bueno, Alexis M. Kalergis · 2026 · iScience
27. Inactivation of Wild Poliovirus with β-Propiolactone
    Anastasia A. Kovpak, Sergei Pashkov, М. А. Кострова et al. · 2026 · Vaccines
28. Multidimensional interactions of living materials with biological entities
    Du Shuqing, Yanfei Liu, Yongbo Liu, Yifu Tan, Yunqi Man, Zhirou Zhang, Zexiang Lv, Luke P. Lee, Qi‐Wen Chen, Zhenbao Liu · 2026 · Biomaterials
29. Toward broad-spectrum coronavirus vaccines: navigating viral evolution from past epidemics to future resilience
    Muzhuo Wang, Weijie Wang, Zhikai Chen, Lu Lu, Zezhong Liu, Shibo Jiang · 2026 · Microbiology and Molecular Biology Reviews
30. Engineered macroscopic hydrogels as local drug delivery devices for controlled release of macromolecular therapeutics
    Zhenyu Luo, Ziru Zhang, Yilin Yu, Jianping Zhou, Huaqing Zhang, Yang Ding, Jiang Ni · 2026 · Chinese Chemical Letters
31. Distinct antibody responses to SARS-CoV-2 in children and adults
    Donna Farber · 2021 · ImmPort
32. BindingDB Entry 50018381: COVID-19 therapy: What weapons do we bring into battle?
    BindingDB · 2024 · UC San Diego
33. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19
    Shane Crotty, Alessandro Sette · 2021 · ImmPort
34. Kinetics of immunological memory to SARS-CoV-2
    Shane Crotty, Alessandro Sette, Daniela Weiskopf · 2022 · ImmPort
35. Summary
    Shane Crotty, Alessandro Sette, Daniela Weiskopf · 2022 · ImmPort